RxDoctor Payments Data

Nathan Wyatt, MD

Neurology · Chattanooga, TNNPI 1396989786

Payments from drug & device makers

$16,046in general payments, 2019–2025

Across 941 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$988
  • Pfizer$821
  • Novartis$673
  • Biohaven Pharmaceuticals, Inc.$618
  • Acadia Pharmaceuticals Inc$609
  • plus $9K from 50 others

What the payments were for

  • Speaking & faculty fees$380%
  • Food & beverage$15,86399%
  • Education$1451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)298$3,830
UCB, Inc.40$988
Pfizer52$821
Novartis35$673
Biohaven Pharmaceuticals, Inc.44$618
Acadia Pharmaceuticals Inc36$609
EMD Serono, Inc.33$589
AstraZeneca(2 entities)27$572
Bristol Myers Squibb43$550
Neurocrine Biosciences, Inc.30$521
Neurelis, Inc.19$499
Biogen24$411
Teva Pharmaceuticals USA, Inc.22$383
TG Therapeutics, Inc.13$362
Amgen(2 entities)17$349
CSL Behring14$341
MDD US Operations, LLC15$310
Argenx US, Inc.13$292
Kyowa Kirin, Inc.11$218
Lilly USA, LLC12$217
Sanofi9$206
Genentech USA, Inc.9$177
Supernus Pharmaceuticals, Inc.11$172
Scilex Pharmaceuticals Inc.9$157
Lundbeck LLC7$156
Eisai Inc.8$153
Johnson & Johnson10$147
SK Life Science, Inc.6$146
Axsome Therapeutics, Inc.5$138
Alnylam Pharmaceuticals Inc.4$118
Banner Life Sciences, LLC6$111
Merz Pharmaceuticals, LLC4$103
Avanir Pharmaceuticals, Inc.5$93
Octapharma USA, Inc.4$85
Sunovion Pharmaceuticals Inc.5$85
Biohaven Pharmaceutical Holding Company Ltd.4$83
Catalyst Pharmaceuticals, Inc.3$72
Adamas Pharmaceuticals, Inc.3$69
Ipsen Biopharmaceuticals, Inc3$63
Acorda Therapeutics, Inc3$56
Mallinckrodt Hospital Products Inc.2$55
Takeda Pharmaceuticals U.S.A., Inc.2$52
Mallinckrodt Enterprises LLC3$48
Sumitomo Pharma America, Inc.2$44
Impel Pharmaceuticals Inc.1$36
Upsher-smith Laboratories LLC2$36
Assertio Therapeutics, Inc.2$32
Jazz Pharmaceuticals Inc.1$32
E.r. Squibb & Sons, L.L.C.2$30
Tanabe Pharma America, Inc.2$25
Livanova USA, Inc.1$23
Medtronic1$22
Boston Scientific1$20
Grifols USA, LLC1$18
Amneal Pharmaceuticals LLC1$16
Arbor Pharmaceuticals, Inc.1$15

How this compares

$16,046 in reported general payments places this provider in the 65th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,600,186
Medicare patients
615
Services billed
43,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EvrysdiRisdiplam16$445,107
OctagamImmun Globg(Igg)/Malt/Iga Ov5047$428,972
NuplazidPimavanserin Tartrate26$164,817
VumerityDiroximel Fumarate14$140,403
Aimovig AutoinjectorErenumab-Aooe69$55,339
UbrelvyUbrogepant34$44,364
Emgality PenGalcanezumab-Gnlm61$41,368
Nurtec OdtRimegepant Sulfate14$22,171
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone68$18,511
QuliptaAtogepant15$15,545
XcopriCenobamate12$13,600
Lacosamide100$12,005
VimpatLacosamide11$11,672
Carbidopa-LevodopaCarbidopa/Levodopa299$10,069
Emgality SyringeGalcanezumab-Gnlm12$9,986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt, Dilantin$821$455,72874 claims
Genentech USA, Inc.Evrysdi$177$445,10716 claims
Acadia Pharmaceuticals IncNuplazid$609$164,81726 claims
BiogenVumerity$411$140,40314 claims
AbbVieUbrelvy, Qulipta$3,830$59,90849 claims
SK Life Science, Inc.Xcopri$146$13,60012 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$16$13,376105 claims
UCB, Inc.Vimpat$988$11,67211 claims
Upsher-smith Laboratories LLCTopiramate$36$1,859183 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 361 neurology providers in Tennessee.

Other neurology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →